Pharmaceutical - Novo Nordisk, Metabolics

Filter

Current filters:

Novo NordiskMetabolics

Popular Filters

Novo Nordisk’s obesity drug Saxenda approved by FDA

Novo Nordisk’s obesity drug Saxenda approved by FDA

24-12-2014

Continuing its rush of year-end drug approvals, the US Food and Drug Administration late yesterday approved…

MetabolicsNovo NordiskPharmaceuticalRegulationSaxendaUSA

New Phase IIIa data further demonstrate benefits of liraglutide in obesity

04-11-2014

Positive new data from the Phase IIIa SCALE Obesity and Prediabetes trial were presented today at Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchSaxendaVictoza

Novo Nordisk establishes new obesity research unit in Seattle

Novo Nordisk establishes new obesity research unit in Seattle

26-09-2014

Danish diabetes care giant Novo Nordisk yesterday announced that the company will establish a new obesity…

ManagementMetabolicsNovo NordiskPharmaceuticalResearchSaxendaUSA

FDA advisory votes to approve Novo Nordisk diabetes drug for obesity

FDA advisory votes to approve Novo Nordisk diabetes drug for obesity

12-09-2014

There was good news for Danish diabetes care giant Novo Nordisk yesterday, when the US Food and drug…

liraglutideMetabolicsNovo NordiskPharmaceuticalRegulationSaxenda

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

23-06-2014

New data for Danish diabetes care giant Novo Nordisk’s liraglutide 3mg from the Phase IIIa SCALET Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Significantly greater weight loss versus placebo seen in Ph IIIa study of liraglutide 3mg

16-05-2014

Significant weight loss was demonstrated for Danish insulin giant Novo Nordisk’s diabetes drug liraglutide…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Novo Nordisk files for approval of high strength liraglutide for obesity

Novo Nordisk files for approval of high strength liraglutide for obesity

22-12-2013

Danish insulin giant Novo Nordisk has filed separate regulatory submissions with the US Food and Drug…

DiabetesEuropeliraglutideMetabolicsNorth AmericaNovo NordiskPharmaceuticalRegulationVictoza

Novo Nordisk aims to expand its already leading position in diabetes care

Novo Nordisk aims to expand its already leading position in diabetes care

03-12-2013

Denmark-based global insulin giant Novo Nordisk this morning set out its ambition to further expand its…

DiabetesHematologyliraglutideMetabolicsNovo NordiskOG217SCPharmaceuticalsemaglutideVictoza

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

20-11-2013

Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNovo NordiskPharmaceuticalVictoza

Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial

24-05-2013

Danish insulin giant Novo Nordisk (NOV: N) has released headline results from a 56-week double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

New study shows Novo Nordisk's Victoza achieves 6% weight loss in type 2 diabetes patients

18-03-2013

Danish insulin giant Novo Nordisk (NOVN: N) has released headline results from a 56-week, double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top